Chr. Hansen Holding

Mindre end 1K følgere

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse29.1.2024, 10.26

Completion of the combination between Novozymes and Chr. Hansen

Chr. Hansen Holding

Selskabsmeddelelse26.1.2024, 11.09

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen

Chr. Hansen Holding

Pressemeddelelse20.12.2023, 14.02

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted

Chr. Hansen Holding

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse19.12.2023, 10.54

Major shareholder announcement from Burlington Loan Management DAC

Chr. Hansen Holding

Pressemeddelelse12.12.2023, 16.11

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: Conditional competition clearance from the European Commission obtained

Chr. Hansen Holding

Selskabsmeddelelse20.11.2023, 07.03

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

Chr. Hansen Holding

Selskabsmeddelelse2.11.2023, 12.10

Managers' Transaction

Chr. Hansen Holding

Selskabsmeddelelse13.10.2023, 13.15

Managers' Transactions

Chr. Hansen Holding

Selskabsmeddelelse12.10.2023, 06.02

Chr. Hansen Holding A/S Interim Report Q4 2022/23

Chr. Hansen Holding

Selskabsmeddelelse10.10.2023, 06.08

Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen

Chr. Hansen Holding

Selskabsmeddelelse27.9.2023, 07.23

Major shareholder announcements from Burlington Loan Management DAC and Davidson Kempner Capital Management LP

Chr. Hansen Holding

Selskabsmeddelelse4.9.2023, 09.48

Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion

Chr. Hansen Holding

Selskabsmeddelelse6.7.2023, 06.03

Chr. Hansen Holding A/S Interim Report Q3 2022/23

Chr. Hansen Holding

Selskabsmeddelelse13.4.2023, 06.02

Chr. Hansen Holding A/S Interim Report Q2 2022/23

Chr. Hansen Holding

Selskabsmeddelelse30.3.2023, 16.07

Novozymes’ and Chr. Hansen’s shareholders approve combination to create a leading global biosolutions partner

Chr. Hansen Holding

Selskabsmeddelelse30.3.2023, 15.57

Resolutions passed at the Extraordinary General Meeting of Chr. Hansen Holding A/S

Chr. Hansen Holding

Selskabsmeddelelse30.3.2023, 11.11

Combination between Novozymes and Chr. Hansen approved by Novozymes’ shareholders

Chr. Hansen Holding

Selskabsmeddelelse28.3.2023, 10.07

Update on the combination of Novozymes and Chr. Hansen: U.S. antitrust regulation waiting period has expired, supporting the path to completion

Chr. Hansen Holding

Selskabsmeddelelse8.3.2023, 07.05

Notice to convene Extraordinary General Meeting

Chr. Hansen Holding

Selskabsmeddelelse8.3.2023, 07.00

Publication of exemption document in relation to the proposed combination of Chr. Hansen and Novozymes, confirmation of outlook for 2022/23 and proposed candidates to the Board of Directors of the combined company

Chr. Hansen Holding

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.